FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Public Meeting on Drug Supply Chain Security

Federal Register notice: FDA announces a 12/7-8 virtual public meeting entitled Drug Supply Chain Security Act Implementation and Readiness Efforts fo...

latest-news-card-1
Human Drugs

Reject FDA Privilege Claim in FOIA Case: WLF

Washington Legal Foundation says the DC Circuit federal court should grant summary judgment in favor of a Vanda Pharmaceuticals suit seeking to compel...

latest-news-card-1
Medical Devices

RapidAIs Lastest Version of Rapid ICH Cleared

FDA clears a RapidAI 510(k) for the latest release of Rapid ICH, an intracranial hemorrhage triage and notification product.

latest-news-card-1
Human Drugs

Panel Votes Down Veru Covid Therapy

An FDA advisory committee votes 8 to 5 to recommend against an emergency use authorization for Verus investigational prostate cancer drug VERU-111 (sa...

latest-news-card-1
Human Drugs

NatureLab Adulterated and Misbranded Dietary Supplements

FDA warns Carrollton, TX-based NatureLab about adulterated and mislabeled dietary supplements.

latest-news-card-1
Human Drugs

CGMP Violations at Abraxis Bioscience

FDA warns Phoenix, AZ-based Abraxis Bioscience about CGMP violations in its manufacturing of finished pharmaceuticals.

latest-news-card-1
Human Drugs

ANDA Sameness Evaluation Guidance

FDA publishes a draft guidance with recommendations on how ANDA applicants can demonstrate sameness between the active ingredient in the proposed gene...

latest-news-card-1
Human Drugs

FDA Raises Sabizabulin Uncertainties

FDA raises uncertainties with Verus request for Covid-19 treatment emergency use authorization for its repurposed investigational cancer drug sabizabu...

latest-news-card-1
Human Drugs

Omeros Loses Appeal on Stem Cell Transplant Drug

CDERs Office of New Drugs denies an Omeros appeal of complete response letter on its BLA for narsoplimab as a treatment for hematopoietic stem cell tr...

latest-news-card-1
Federal Register

Review Period for AngelMed Guardian System

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Angel Medical Systems AngelMed Guardian System....